Ischemic heart disease remains the primary cause of morbidity and mortality in the Western world. Current therapeutic strategies are aimed at relieving the ischemia by opening blocked arteries; however, no current therapies can directly protect the heart and ensure ongoing heart function. Faced with this challenge, Walter J. Koch and fellow researchers at Duke University Medical Center, North Carolina, have developed a strategy whereby delivery of erythropoietin (EPO), shortly after ischemic injury, was shown to enhance heart function and prevent subsequent smaller attacks by inhibiting cardiac myocyte cell death.
These results, reported in the October 1 issue of the Journal of Clinical Investigation, demonstrate that a therapeutic window of opportunity may exist in which a single dose of EPO following myocardial infarct, cardiac surgery or other acute coronary syndromes may offer acute protection as well as long term preservation of the ischemic and infarcted heart.
TITLE: A novel protective effect of erythropoietin in the infarcted heart
Walter J. Koch
Jefferson Medical College, Philadelphia, Pennsylvania, USA.
View the PDF of this article at: https://www.the-jci.org/press/18200.pdf
A dangerous duo: heart disease and diabetes
The prevalence of obesity and diabetes is increasing worldwide and diabetes currently represents the leading cause of blindness, renal failure, and amputation in the USA. However, these conditions can be slowed or prevented by controlling glucose levels within the body. Interestingly, individuals with diabetes have a two to four-fold higher risk of developing heart dis
Contact: Brooke Grindlinger
Journal of Clinical Investigation